In vitro drug resistance versus chemosensitivity: Two sides of different coins [10]

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3641-3643

  Fruehauf, John P ^a   Alberts, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; CLONOGENIC ASSAY; DRUG RESISTANCE; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; LETTER; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICARE; OVARY CANCER; OVERALL SURVIVAL; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECT; DRUG SCREENING; ECONOMICS; METHODOLOGY; NEOPLASM; NOTE; SENSITIVITY AND SPECIFICITY; STANDARD; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GUIDELINES; HUMANS; MEDICARE; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 20644459931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.281     Document Type: Letter

References (17)

1. Schrag D, Garewal HS, Burstein HJ, et al: American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 22:3631-3638, 2004
2. Medicare Coverage: MCAC Laboratory and Diagnostic Services Panel Human Tumor Assay Systems. Minutes of November 15-16, 1999, Meeting. http://www.cms.hhs.gov/mcd/viewmcac.asp?where=index&id=36
3. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications. PPO Updates, Principles and Practices of Oncology 7:1-17, 1993
4. Fruehauf JP: Assay Assisted Treatment Selection for Women with Breast or Ovarian Cancer. Endocrine-Related Cancer 9:171-182, 2002
5. Chu E, DeVita VT. Principles of cancer management chemotherapy, in DeVita VT, Hellman S, Rosenberg S (eds): Cancer: Principles & Practice of Oncology (ed 6). Philadelphia, PA, Lipincott, Williams and Wilkins, 2001, pp 289-306
6. Alberts DS, Samon SE, Chen HS, et al: In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2:340-342, 1980
7. Brown E, Markman M: Tumor chemosensitivity and chemoresistance assays. Cancer 77:1020-1025, 1996
8. Von Hoff DD: He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:96-101, 1990
9. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro sensitivity testing for patients with cancer. J Clin Oncol 17:1625-1631, 1999
10. Clark GM, Von Hoff DD: Quality control of a multicenter human tumor cloning system: The Southwest Oncology Group experience, in Salmon SE, Trent JM (ed): Human Tumor Cloning. New York, NY, Grune & Startton, 1984. pp 255-265
11. Bosanquet AG, Johnson SA, Richards SM: Prognosis for fludarabine therapy of chronic lymphocytic leukemia based on ex vivo cytotoxic drug response by DiSC assay. Br J Haematol 106:71-77, 1999
12. Weisenthal LM: Clinical correlations for cell culture assays based on the concept of total tumor cell kill. Contrib Gynecol Obstet 19:82-90, 1994
13. Mehta RS, Bornstein R, Yu IR, et al: Breast cancer survival and in vitro tumor response in the Extreme Drug Resistance Assay. Breast Cancer Res Treat 66:225-237, 2001
14. Holloway RW, Mehta RS, Finkler NJ, et al: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87:8-16, 2002
15. Tewari K, Mehta RS, Burger RA, et al: Conservation of in vitro drug resistance profiles in epithelial ovarian cancer. Gynecol Oncol 98: in press, 2005
16. Salmon SE, Hamburger AW, Soehnlen B, et al: Quantitation of differential sensitivity of human tumor stem cells to anti-cancer drugs. New Engl J Med 298:1312-1325, 1978
17. Loizzi V, Chan JK, Osann K, et al: Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189:1301-1307, 2003